# Omission of axillary dissection after neoadjuvant systemic treatment in initially node-positive HER2-overexpressed and triple-negative breast cancer patients: SENATURK OTHER-NAC study.

**Autores:** Cab&#x131;o&#x11f;lu N, Karanl&#x131;k H, &#x130;&#x11f;ci A et al.
**Revista:** Eur J Surg Oncol (2025)
**PMID:** 40009910 | **PMCID:** —
**DOI:** [10.1016/j.ejso.2025.109642](https://doi.org/10.1016/j.ejso.2025.109642)
**Fuente:** PubMed (abstract only — full text vía DOI)

## Relevancia
Describe respuesta y manejo axilar tras NAC en enfermedad nodal avanzada (cN2/cN3), donde la conversión a ypN0 es menos frecuente pero clínicamente relevante para decidir extensión quirúrgica.

## Abstract
More data is needed for those patients with aggressive tumor biology with a high recurrence risk for de-escalating axillary surgery in clinically N+ breast cancer. We, therefore, investigated the outcome in cN+&#xa0;patients with HER2+ or triple-negative breast cancer who were treated with sentinel lymph node biopsy alone following neoadjuvant systemic treatment.

Clinically N+ patients (cTNM) with HER2+ and triple-negative breast cancer at admission and downstaged to cNwith neoadjuvant systemic treatment were included in the study. All patients were treated with sentinel node biopsy alone without further axillary dissection but followed by regional nodal irradiation.

Of 259 patients, the pathologic complete response rate was 47.1&#xa0;%. Overall, 171 (66&#xa0;%) patients had HER2+ and 88 (34&#xa0;%) had triple-negative cancer. Of 56 ypN+&#xa0;patients, the lymph node metastases were macrometastases in 24 (42.9&#xa0;%) patients. After a median follow-up of 46 months, irrespective of ypN status, isolated axillary, locoregional, and distant recurrence rates were 0.8&#xa0;%, 2.7&#xa0;%, and 7.7&#xa0;%, respectively. Recurrence and disease-specific death rates were not different between HER2+ and triple-negative cancer as well as ypNand ypNpatients. Advanced cT stage (cT) was the only significant factor associated with poor disease-free and disease-specific survivals.

Irrespective of the final ypN status and tumor subtype, omission of axillary dissection resulted with low axillary recurrence rate in initially cN+&#xa0;HER2+ and triple-negative breast cancer patients who were downstaged to cNwith neoadjuvant systemic treatment and did not receive axillary dissection.

## Acceso
Vía [DOI](https://doi.org/10.1016/j.ejso.2025.109642) o suscripción institucional.

---
*Datos de PubMed. Citar: doi 10.1016/j.ejso.2025.109642*
